Wednesday, July 8, 2026

biotech · Non-muscle Invasive Bladder Cancer · Intestinal Failure · TARA

Protara Therapeutics

Protara Therapeutics is a biotech organization headquartered in New York, USA. It trades on NYSE under ticker TARA. Primary therapeutic focus areas include Non-muscle Invasive Bladder Cancer, Intestinal Failure, Choline

New York, USA HQ
2017 Founded
56 Employees
Public company Type
TARA · NYSE Ticker
Company details
Status
Public
HQ
New York, USA
Founded
2017
Employees
56
Programs
7
Drugs
10
Patents
2
Clinical program

Subcutaneous depot medroxyprogesterone acetate

Approved · small molecule · Contraception

Subcutaneous depot medroxyprogesterone acetate for Contraception is a Approved program (small_molecule) at Protara Therapeutics with 1 ClinicalTrials.gov record(s).

← All Protara Therapeutics projects Approved small molecule completed

Internal code Pro00012433

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Protara Therapeutics
Phase
Approved
Modality
small_molecule
Indication
Contraception
Status
completed
Trials
1